This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in Alzheimer’s disease (AD) market, including; Novartis and Amgen, together with the Banner Alzheimer’s Institute, launching a new Phase II/III study with beta-secretase-1 inhibitor, CNP520 in an asymptomatic, high-risk population; IntelGenx initiating a Phase IIa study of Montelukast VersaFilm for patients with mild-to-moderate AD; ProMIS Neurosciences announcing results from a preclinical study of its next generation monoclonal antibody for AD, PMN310.
What are KOL’s current views on the amyloid theory of AD?
Is research into preventative medications a feasible approach with the drug candidates that are currently available?
What are the key barriers to research into disease prevention and modification?
How does CNP520 compare to other BACE inhibitors?
What do KOLs believe will be the best development strategy for Montelukast VersaFilm in AD?
Is PMN310 sufficiently differentiated from other anti-amyloid antibodies to merit further research?
How do experts rate the likelihood of success of these new developments?
Do KOLs expect combination therapy to play a major role in the future treatment of AD?
What are the barriers to combination therapy in AD?